Decision Resources’ findings, based on the Pharmacor topic “Prostate Cancer,” revealed that the launches of several promising emerging therapies for prostate cancer will drive the market’s growth from $3.6 billion in 2010 to almost three times that amount over the next 10 years.
Related Articles on Hospital Oncology:
Prostate Cancer Patients May See Better Outcomes at Academic Hospitals
Kansas’ Via Christi Hospital Joins Midwest Cancer Alliance
Barnes-Jewish Hospital Installs First-of-its-Kind Proton Accelerator
